Economic Analysis of Decitabine Versus Best Supportive Care in the Treatment of Intermediate- and High-Risk Myelodysplastic Syndromes From a US Payer Perspective

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2444-2456

  Pan, Feng ^a   Peng, Siyang ^a   Fleurence, Rachael ^a   Linnehan, John E ^a   Knopf, Kevin ^b   Kim, Edward ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c EISAI INC   (United States)

Author keywords

Acute myeloid leukemia; Cost effectiveness; Decitabine; Economic; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COLONY STIMULATING FACTOR; DEFEROXAMINE; RECOMBINANT ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RISK; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; ERYTHROCYTE TRANSFUSION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTPATIENT CARE; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL MODEL; THROMBOCYTE TRANSFUSION; UNITED STATES;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MARKOV CHAINS; MODELS, ECONOMIC; MYELODYSPLASTIC SYNDROMES; PATIENT CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; UNITED STATES;

EID: 79951846842     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.12.003     Document Type: Article

References (35)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Oscier D.G. ABC of clinical haematology. The myelodys-plastic syndromes. BMJ 1997, 314:883-886.
3. Szende A., Schaefer C., Goss T.F., et al. Valuation of transfusion-free living in MDS: Results of health utility interviews with patients. Health Qual Life Outcomes 2009, 7:81.
4. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neo-plasms. Blood 2002, 100:2292-2302.
5. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
6. Frytak J.R., Henk H.J., De Castro C.M., et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009, 25:1941-1951.
7. Disperati P., Ichim C.V., Tkachuk D., et al. Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology. Leuk Res 2006, 30:233-239.
8. Lang K., Earle C.C., Foster T., et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2005, 22:943-955.
9. Oberg G., Killander A., Björeman M., et al. Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy. Eur J Haematol 2002, 68:376-381.
10. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 31(Suppl 3):S2-S6.
11. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006, 106:1794-1803.
12. Dacogen (decitabine) for injection [product information] Accessed November 17, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021790lbl.pdf.
13. Dacogen (decitabine) for injection [product information] Accessed November 17, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021790s006lbl.pdf.
14. Valent P., Horny H.P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
15. Steensma D.P., Baer M.R., Slack J.L., et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
16. Slovacek L., Slovackova B., Jebavy L., Macingova Z. Psychosocial, health and demographic characteristics of quality of life among patients with acute myeloid leukemia and malignant lymphoma who underwent autologous hematopoietic stem cell transplantation. Sao Paulo Med J 2007, 125:359-361.
17. Uyl-de Groot C.A., Löwenberg B., Vellenga E., et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998, 100:629-636.
18. Alibhai S.M., Leach M., Kermalli H., et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol 2007, 64:19-30.
19. Brooks R. EuroQol: The current state of play. Health Policy 1996, 37:53-72.
20. Kontodimopoulos N., Aletras V.H., Paliouras D., Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009, 12:1151-1157.
21. Thomson P.D.R. Red Book for Windows. Version 61127 2009, Thomson PDR, Montvale, NJ.
22. Physician's Fee and Coding Guide, vol 1 2009, MAG Mutual Healthcare Solutions Inc, MAG Mutual Healthcare Solutions Inc, Duluth, Ga.
23. The Healthcare Cost and Utilization Project (HCUP) Agency for Healthcare Research and Quality, Accessed November 2009. http://www.ahrq.gov/data/hcup/.
24. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood. 1998;91:1100]. Blood 1997, 89:2079-2088.
25. Fast Stats: An interactive tool for access to SEER cancer statistics Surveillance Research Program (SEER), Accessed August 6, 2010. http://seer.cancer.gov/faststats.
26. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodys-plastic syndromes: A randomized, controlled trial. Blood 2004, 104:321-327.
27. Gattermann N., Hofmann W.K., Meessen A., et al. Myelodysplastic syndromes: Aspects of current medical care and economic considerations in Germany. Onkologie 2008, 31:477-484.
28. Greenberg P.L., Cosler L.E., Ferro S.A., Lyman G.H. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008, 6:942-953.
29. Gupta P., LeRoy S.C., Luikart S.D., et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications. Leuk Res 1999, 23:953-959.
30. O'Brien J.A., Caro J.J. Managing myelodysplastic syndromes with supportive therapy in elderly persons. Drug Benefit Trends 2005, 17:341-351.
31. Goss T.F., Szende A., Schaefer C., et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006, (Suppl 13):17-25.
32. Miller JD, Fenaux P, Beach CL, et al. Comparative cost-effectiveness of azacitidine versus decitabine for the treatment of myelodysplastic syndromes (MDS). Abstract presented at: 51st ASH Annual Meeting and Exposition; December 5, 2009; New Orleans, La.
33. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodys-plastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232. International Vidaza High-Risk MDS Survival Study Group.
34. Claxton K., Sculpher M., McCabe C., et al. Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Econ 2005, 14:339-347.
35. Bordoni R, Feinberg B, Gilmore J, et al. Hematologic outcomes of MDS treatment with hypomethylating agents in community practice. Poster presented at: 2010 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, Ill.